PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

38,655 stories, page 316 of 645

Advanced search
🌍discoverynews.google.comTier 3 · Aggregated media

Lexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission

Quiver QuantitativeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial

Proactive financial newsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO)

The Globe and MailOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Avalo Therapeutics Announces Plans for Phase 3 Abdakibart HS Program, Advancement of AVTX-010 and Second Quarter 2026 Financial Results

Quiver QuantitativeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Intellia Therapeutics Reports Positive Phase 3 HAELO Data for Lonvo-z, Advances Nex-z Trials and Reaffirms Cash Runway Into 2028

Quiver QuantitativeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership

Quiver QuantitativeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Ocugen Reports Q2 2026 Results, Advances OCU410 Phase 3, Secures RMAT Designation and $130 Million Financing

Quiver QuantitativeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Intellia TherapeuticsOriginal source
🌍Industrytizianalifesciences.comTier 1 · Company source

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life SciencesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pharvaris Publishes Study on AAE-C1INH Patient Experience, Informing Phase 3 CREAATE Trial Design

Quiver QuantitativeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Kodiak's Trial Tests KSI-101 for Macular Edema Secondary to Inflammation

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Compass Pathways' Aug. 12 Fireside Chat Will Have Live Webcast

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data

Business WireOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Painful swelling and misdiagnoses disrupted daily life in Pharvaris study

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pharma companies reported fewer medicine supply issues in 2026

The Pharmaceutical JournalOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

Why the government must urgently raise the NICE cost-effectiveness threshold

ABPI UKOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

International comparisons in medicines spending and the link to competitiveness

ABPI UKOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

Laura McMullin of Daiichi Sankyo named as new ABPI Vice-President

ABPI UKOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

Growth and skills levy: A catalyst for the UK pharmaceutical industry?

ABPI UKOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Biotech’s next big bet: A Tenax study of a heart failure treatment

STATOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

Gen Z are turning to TikTok for career advice and inspiration, finds new report

ABPI UKOriginal source
🌍discoverynews.google.comTier 2 · Trade media

‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E

Fierce BiotechOriginal source
🇺🇸Devicesinvestors.bd.comTier 1 · Company source

BD Reports Third Quarter Fiscal 2026 Financial Results

Becton Dickinson (BD)Original source
🌍discoverynews.google.comTier 2 · Trade media

Eli Lilly raises 2026 outlook again as Q2 soars past estimates

Pharmaceutical TechnologyOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

Reinventing Reputation: one of pharma's biggest challenges

ABPI UKOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

ABPI respond to Wes Streeting’s commitment to boosting the economy through the life sciences sector

ABPI UKOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Rethinking sterile product development for manufacturing success

Pharmaceutical TechnologyOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

ABPI welcomes Labour's life sciences plan

ABPI UKOriginal source
🇺🇰Regulatoryabpi.org.ukTier 1 · Regulatory source

Understanding NHS medicines spending in England

ABPI UKOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Gillibrand, Scott seek FDA plan on chemotherapy drug shortages

fingerlakes1.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Mergers as Strategic Architecture: Rethinking How to Evaluate the AstraZeneca–BMS Rumors

Pharmaceutical ExecutiveOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027

Fierce BiotechOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Centre imposes tougher penalties for fake drug approval data

The Assam TribuneOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial

Streetwise ReportsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Glenmede Trust Co. NA Acquires 44,273 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Onconic’s GERD drug Jaqbo wins first overseas approval in India

koreabiomed.comOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Why global pharmaceutical reforms are quietly redirecting rare disease innovation

pharmaphorumOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

AL biotech facility focused on rare diseases to close, lay off 47

The Tuscaloosa NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Biotech Stocks At 52-Week Highs - BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS

RTTNewsOriginal source
🇩🇪Researchuni-heidelberg.deTier 2 · Direct publisher

Plant Cells: Cleanup Program Regulates Immune Response to Viral Infections

Heidelberg UniversityOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Cosmogen & Asquan equip biotech beauty brand with refill sun care stick

Packaging InsightsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

How Burning Rock Biotech Limited (BNR) Affects Rotational Strategy Timing

Stock Traders DailyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBIT forward of Innovation1 Biotech Inc. – OTC:IVBT

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA seizes Rs 55.72 crore worth of unsafe food, suspends 165 licences in two-month crackdown

Mid-DayOriginal source
🇺🇰Researchukri.orgTier 2 · Direct publisher

Global Talent visa expanded to innovative research businesses

Medical Research Council (UKRI)Original source
🌍Mediaskpharmteco.comTier 3 · Secondary coverage

Rare Disease Blog Part XII: Breakthroughs 2025–2026: FDA Firsts, Patient-Specific CRISPR, and the New Access Playbook

SkpharmtecoOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Portable gas detection in the pharmaceutical sector

Manufacturing ChemistOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Cumberland Pharmaceuticals (CPIX) Stock Cools As Cash Rich Biotech Pivot Begins

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

TABLE-Fuji Pharmaceutical - 9-MTH group results

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

This simple tool may bring caries to a halt

DrBicuspid.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Promising treatments for aggressive cancer emerge from phase 3 trial

Dagens.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

K-Pharma Expands Push Into Latin America

BusinesskoreaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Ultragenyx (RARE) Stock Revenue Record Clashes With Ongoing Cash Burn

simplywall.stOriginal source
🇧🇪Regulatoryfamhp.beTier 1 · Regulatory source

Model van diergeneeskundig voorschrift: nieuwe verplichte vermeldingen

FAMHP BelgiumOriginal source
🌍discoverynews.google.comTier 2 · Trade media

CROs vs. biotechs: Finding the right fit

biospace.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale?

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA to fast-track restoration of suspended food business licences: Tukaram Mundhe

Mid-DayOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBIT forward of Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A – SZSE:301126

TradingViewOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

biospace.comOriginal source
🇺🇸Industry4gclinical.comTier 1 · Company source

Dose Movement Needed Structure - Science in Motion Series

4G ClinicalOriginal source